#ASCO25 👀 at some of these responses! 👇🏽These are patients with MSS🧊(“cold tumors”), not the MSI-High🔥(“hot tumors”). This is a big unmet need in colorectal cancer and other cancers.

🔗

Vilastobart (XTX101)
Tumor-activated CTLA4⛔️
➕PDL1-

@OncoAlert meetings.asco.org/abstracts-pres… And not just lung 🫁 only metastases, but also peritoneal. #CRCSM

@OncoAlert @mgfakih presenting. Out now.

#GI25🎤drop #NEST🪺🙋🏻‍♂️🙌🏽

|➖➖➖➖➖➖➖➖➖➖ 💯
|
|
|
|
|
|
|
|
|—————————————————

✅NO RECURRENCES📅!

💡Neoadjuvant immunotherapy keeps delivering!

👉🏽Patients with MSS🧊NOT just MSI-High🔥colorectal #cancer.

Goal is to👏🏾*CURE*👏🏾more patients.

🔜Phase2/3
@OncoAlert @ASCO We also helped answer an important question. Do responses deepen by letting #immunotherapy brew🫖for longer. You can visually see surgery timing ⏱️ :

🔵~4 weeks
🆚
🔴~8 weeks

the proportion% of nearCR ➕ pathCR (major pathologic responses) ~ 2️⃣✖️.

@OncoAlert #GI25 #NEST 🪺

Published today! 📰
@NatureMedicine

One of the first #cancer vaccines💉that target #KRAS. Not just G12C.
👇🏾The 2-peptide was G12D & R.
The 7-Peptide/Elicio targets
D
R
V
S
A
C
G13
➕
NRAS

Implications for so many patients!
Open now.
Cheers!
@OncoAlert

nature.com/articles/s4159…
This is a groundbreaking study in so many respects.

Besides the fact that the vaccine worked, many unique/powerful aspects👇🏾.

First: how did we enroll?
#ctDNA🩸🧬🙌🏾✅

Patients with pancreas & colorectal cancer. Those who had persistence of disease post-curative intent therapy.

What is the #CityOfHopeDrug?

A pill💊that can kill all #cancers.

I have been asked the "killer-pill" question several times this week. What is the hope or the hype?

Let’s learn together:
👇Here’s a tweetorial: @OncoAlert

Press release: August 1, 2023:
https://t.co/o5HNKEgIApcityofhope.org/city-hope-scie…
The study was published in the journal Cell Chemical and Biology.

"Small molecule targeting of transcription-replication conflict for selective chemotherapy."

Link to journal article:


It targets DNA🧬 replication/transcription simplistically speaking. https://t.co/5HEcipZRpVcell.com/cell-chemical-…

Yesterday at #TargetedChat we talked about a challenging case of a young individual with recurrent UNRESECTABLE colon cancer after adjuvant.

Here’s a 🧵 on the questions/answers. No one right away. What would you do differently?👇🏾Read/reply along #ColorectalCancerAwarenessMonth

https://twitter.com/TargetedOnc/status/1508826169436688391

It was interesting to see the distribution on the chemo backbone options.

TRIPLETS 🆚 DOUBLETS #TargetedChat #CRCSM

https://twitter.com/TargetedOnc/status/1508810049422073866

#GI21 time for another #Tweetorial🧵 on

#LiquidBiopsies
#CirculatingTumorDNA
#ctDNA

in a very 🎯 “Target-rich” disease
#Cholangiocarcinoma
#HPBCSM

~3️⃣0️⃣% actionable findings

Interestingly we found more #FGFR🧬 fusions on liquid🩸than tissue 🔬. #OncoAlert
@TempusLabs 🧵2️⃣ #GI21
#Cholangiocarcinoma is the poster child of actionable aberrations & truly a 🎯“Target-rich” disease.

We focused on %numbers for aberrations for which there’s either an ✅approved drug, guideline endorsement, #clinicaltrials or even off-label reports/cases.👇🏾

Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert 🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020